Alunbrig
brigatinib
Table of contents
Overview
Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). It is used in patients who have not been treated before with a medicine of the ALK inhibitor class or who have been treated before with the ALK-inhibitor crizotinib.
Alunbrig is only used if the NSCLC is ‘ALK-positive’, which means that the cancer cells have certain changes affecting the gene that makes a protein called ALK (anaplastic lymphoma kinase).
Alunbrig contains the active substance brigatinib.
-
List item
Alunbrig : EPAR - Medicine overview (PDF/124.09 KB)
First published: 26/11/2018
Last updated: 11/06/2020
EMA/124022/2020 -
-
List item
Alunbrig : EPAR - Risk-management-plan summary (PDF/255.32 KB)
First published: 26/11/2018
Last updated: 11/06/2020
Authorisation details
Product details | |
---|---|
Name |
Alunbrig
|
Agency product number |
EMEA/H/C/004248
|
Active substance |
brigatinib
|
International non-proprietary name (INN) or common name |
brigatinib
|
Therapeutic area (MeSH) |
Carcinoma, Non-Small-Cell Lung
|
Anatomical therapeutic chemical (ATC) code |
L01XE43
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Publication details | |
---|---|
Marketing-authorisation holder |
Takeda Pharma A/S
|
Revision |
9
|
Date of issue of marketing authorisation valid throughout the European Union |
22/11/2018
|
Contact address |
Delta Park 45 |
Product information
24/07/2023 Alunbrig - EMEA/H/C/004248 - R/0049
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.
Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALKpositive advanced NSCLC previously treated with crizotinib.